We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-2.82%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.01B
AUM Growth
-$1.6B
(-35%)
Cap. Flow
-$1.27B
Cap. Flow
% of AUM
-42.02%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$89.8M |
| 2 |
Becton Dickinson
BDX
|
+$70.5M |
| 3 |
Zoetis
ZTS
|
+$66.8M |
| 4 |
Merck
MRK
|
+$64.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$60.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$218M |
| 2 |
argenx
ARGX
|
+$127M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$125M |
| 4 |
Boston Scientific
BSX
|
+$113M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arrowhead Research
ARWR
$12.1B
| $44.2M | 1.47% |
1,741,300
+366,300
| +27% | +$11.5M |
|
27
Pacific Biosciences
PACB
$432M
| $44.1M | 1.47% |
+3,812,600
| New | +$37.9M |
|
|
28
Boston Scientific
BSX
$68.5B
| $42.5M | 1.41% |
850,000
-2,406,700
| -74% | -$113M |
|
29
Axsome Therapeutics
AXSM
$12.1B
| $38.2M | 1.27% |
619,200
-50,800
| -8% | -$3.34M |
|
30
Vir Biotechnology
VIR
$1.49B
| $38.2M | 1.27% |
1,640,200
+790,200
| +93% | +$20.2M |
|
31
Immunocore
IMCR
$1.7B
| $38.1M | 1.26% |
769,800
-384,200
| -33% | -$21.6M |
|
32
Karyopharm Therapeutics
KPTI
$161M
| $37.5M | 1.24% |
642,261
| – | – |
|
33
Abbott
ABT
$187B
| $35.8M | 1.19% |
+354,000
| New | +$37.4M |
|
34
Biogen
BIIB
$30.4B
| $35.8M | 1.19% |
+128,800
| New | +$35.6M |
|
|
BLU
35
DELISTED
BELLUS Health Inc.
BLU
| $32.8M | 1.09% |
4,553,577
-46,421
| -1% | -$360K |
|
36
Icon
ICLR
$13.9B
| $30.5M | 1.01% |
142,900
-72,100
| -34% | -$16M |
|
37
BioMarin Pharmaceuticals
BMRN
$12B
| $29.2M | 0.97% |
+300,575
| New | +$31.2M |
|
38
Revolution Medicines
RVMD
$39.1B
| $29.1M | 0.97% |
1,344,800
-1,130,200
| -46% | -$27.8M |
|
|
ETNB
39
DELISTED
89bio
ETNB
| $28.1M | 0.93% |
+1,842,976
| New | +$24M |
|
40
Amylyx Pharmaceuticals
AMLX
$2.17B
| $26.4M | 0.88% |
+900,000
| New | +$31.3M |
|
|
CVAC
41
DELISTED
CureVac
CVAC
| $24.7M | 0.82% |
+3,550,000
| New | +$30.9M |
|
42
Avantor
AVTR
$8.48B
| $23.8M | 0.79% |
+1,125,000
| New | +$25.6M |
|
|
NSTG
43
DELISTED
NanoString Technologies, Inc.
NSTG
| $21.9M | 0.73% |
2,217,000
+159,800
| +8% | +$1.58M |
|
|
FUSN
44
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $21.5M | 0.71% |
+5,700,000
| New | +$22.4M |
|
45
Rocket Pharmaceuticals
RCKT
$343M
| $21.3M | 0.71% |
1,244,400
-282,687
| -19% | -$5.54M |
|
|
KZR
46
DELISTED
Kezar Life Sciences
KZR
| $20.4M | 0.68% |
651,940
-26,300
| -4% | -$1.52M |
|
47
Biohaven
BHVN
$2.07B
| $20.3M | 0.67% |
1,487,200
-4,800
| -0.3% | -$76.4K |
|
48
Cencora
COR
$62.2B
| $20.3M | 0.67% |
+126,600
| New | +$20.1M |
|
49
Mineralys Therapeutics
MLYS
$2.38B
| $19.8M | 0.66% |
+1,263,800
| New | +$21.3M |
|
|
VERV
50
DELISTED
Verve Therapeutics
VERV
| $19.5M | 0.65% |
1,351,700
-213,300
| -14% | -$4.18M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q1 2023 Portfolio in Review
As of Q1 2023, Avidity Partners Management held 106 positions worth $3.01B, down 35% from $4.62B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Avidity Partners Management withdrew a net $1.27B in Q1 2023, closing 23 positions and reducing 41 holdings. Its most notable exit was United Therapeutics, an estimated $218M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier, followed by Financials.
Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $97.9M.
- Avidity Partners Management's largest Q1 2023 buy was Regeneron Pharmaceuticals: 119,100 shares worth $97.9M.
- Avidity Partners Management added most to Bio-Rad Laboratories Class A in Q1 2023, an estimated $60.5M increase.
- Avidity Partners Management's biggest Q1 2023 reduction was argenx, cutting an estimated $127M.
- Avidity Partners Management fully exited United Therapeutics in Q1 2023, selling an estimated $218M.
- Avidity Partners Management's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2023.
- Avidity Partners Management opened 21 new positions and closed 23 in Q1 2023.
- Avidity Partners Management's portfolio value fell 35% quarter-over-quarter to $3.01B.
Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.